DK0830353T3 - Fremgangsmåde til fremstilling af en HIV-protease-inhiberende forbindelse - Google Patents

Fremgangsmåde til fremstilling af en HIV-protease-inhiberende forbindelse

Info

Publication number
DK0830353T3
DK0830353T3 DK96915755T DK96915755T DK0830353T3 DK 0830353 T3 DK0830353 T3 DK 0830353T3 DK 96915755 T DK96915755 T DK 96915755T DK 96915755 T DK96915755 T DK 96915755T DK 0830353 T3 DK0830353 T3 DK 0830353T3
Authority
DK
Denmark
Prior art keywords
preparing
amino
hiv protease
inhibiting compound
protease inhibiting
Prior art date
Application number
DK96915755T
Other languages
English (en)
Inventor
Jien-Heh Tien
Jerome A Menzia
Arthur J Cooper
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0830353T3 publication Critical patent/DK0830353T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK96915755T 1995-06-06 1996-05-13 Fremgangsmåde til fremstilling af en HIV-protease-inhiberende forbindelse DK0830353T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/469,965 US5567823A (en) 1995-06-06 1995-06-06 Process for the preparation of an HIV protease inhibiting compound
PCT/US1996/006812 WO1996039398A1 (en) 1995-06-06 1996-05-13 Process for the preparation of an hiv protease inhibiting compound

Publications (1)

Publication Number Publication Date
DK0830353T3 true DK0830353T3 (da) 2002-07-29

Family

ID=23865732

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96915755T DK0830353T3 (da) 1995-06-06 1996-05-13 Fremgangsmåde til fremstilling af en HIV-protease-inhiberende forbindelse

Country Status (11)

Country Link
US (1) US5567823A (da)
EP (1) EP0830353B1 (da)
JP (2) JP4580044B2 (da)
AT (1) ATE216696T1 (da)
CA (1) CA2219983C (da)
DE (1) DE69620882T2 (da)
DK (1) DK0830353T3 (da)
ES (1) ES2176456T3 (da)
MX (1) MX9709454A (da)
PT (1) PT830353E (da)
WO (1) WO1996039398A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69305093T2 (de) * 1992-12-29 1997-04-17 Abbott Lab Inhibitoren der retroviralen protease
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6180634B1 (en) * 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
EP1039886A4 (en) * 1997-12-08 2001-05-16 Scripps Research Inst HIV / LIV PROTEASES INHIBITORS WITH SMALL P3 REST
US6803466B1 (en) * 1997-12-08 2004-10-12 The Scripps Research Institute HIV/FIV protease inhibitors having a small P3 residue
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
WO2000074677A2 (en) * 1999-06-04 2000-12-14 Abbott Laboratories Improved pharmaceutical formulations
IT1313624B1 (it) * 1999-09-21 2002-09-09 Archimica Spa Ora Clariant Lif Procedimento per la sintesi del ritonavir
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
EP1248600B1 (en) * 2000-01-19 2008-05-14 Abbott Laboratories Improved hiv protease inhibitors pharmaceutical formulations
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) * 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
BRPI0620865A2 (pt) 2005-12-30 2011-11-29 Gilead Sciences Inc métodos para melhorar a farmacocinética de inibidores das integrases do hiv
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
EP4403221A3 (en) 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
CN101967130B (zh) * 2010-07-02 2012-12-26 厦门市亨瑞生化有限公司 利托那韦中间体的合成方法
CN102786494B (zh) * 2012-07-26 2016-01-06 合肥华方医药科技有限公司 利托那韦异构体杂质的合成研究及控制方法
WO2015125082A1 (en) * 2014-02-21 2015-08-27 Mylan Laboratories Limited Improved process for the preparation of ritonavir
CN104311503B (zh) * 2014-11-03 2017-01-25 东北制药集团股份有限公司 一种制备抗hiv药物利托那韦的方法
CN111646953A (zh) * 2020-04-23 2020-09-11 厦门蔚嘉制药有限公司 一种合成利托那韦的新方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
DE69305093T2 (de) * 1992-12-29 1997-04-17 Abbott Lab Inhibitoren der retroviralen protease

Also Published As

Publication number Publication date
CA2219983C (en) 2007-09-18
DE69620882T2 (de) 2002-12-12
EP0830353B1 (en) 2002-04-24
JP4580044B2 (ja) 2010-11-10
EP0830353A1 (en) 1998-03-25
JP2010270123A (ja) 2010-12-02
JP5390477B2 (ja) 2014-01-15
JPH11507029A (ja) 1999-06-22
WO1996039398A1 (en) 1996-12-12
US5567823A (en) 1996-10-22
ATE216696T1 (de) 2002-05-15
CA2219983A1 (en) 1996-12-12
MX9709454A (es) 1998-02-28
ES2176456T3 (es) 2002-12-01
PT830353E (pt) 2002-10-31
DE69620882D1 (de) 2002-05-29

Similar Documents

Publication Publication Date Title
PT830353E (pt) Processo para a preparacao de um inibidor da protease de hiv
CA2585898A1 (en) Use of (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4-thaizolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane in combination with another protease inhibitor for treating hiv infection
EA200200975A1 (ru) Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона
DK1076644T3 (da) N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser
MX9603909A (es) Derivados de sulfonamida como inhibidores de proteasa aspartilo.
NZ509125A (en) Polymorph of ritonavir ((2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane
EP0839798A3 (en) Intermediates for preparating non-peptide retroviral protease inhibitors
ATE317850T1 (de) 2-((n-(2-amino-3-(heteroaryl- oder - aryl)propionyl)aminoacyl)amino)- alkylboronsäurederivate
EP1637518A3 (en) Inhibitors of aspartyl protease
DK0455789T3 (da) Fremgangsmåde til forebyggelse eller begrænsning af reperfusionsbeskadigelse
EA200101101A1 (ru) Новый фармацевтический препарат
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
CY1107252T1 (el) Τρυγικο αλας παραγωγου της θειζολιδινοδιονης
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
AP1680A (en) Thiazolidinedione derivative and its use as antidiabetic.
DK0854872T3 (da) Fremgangsmåde til fremstillingen af en disubstitueret thiazol
DK1315724T3 (da) Thiazolidindionderivat og dets anvendelse som antidiabetikum
CY1105903T1 (el) Ενα παραγωγο της θειαζολιδενεδιονης και η χρηση του σαν αντιδιαβητικο
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
WO2002024711A1 (en) Novel thiazole bicyclic compounds
EA200300423A1 (ru) Производное тиазолидиндиона и его применение в качестве противодиабетического лекарственного средства
CY1106397T1 (el) Βενζολοσουλφονικη 5-(4-(2-(ν-μεθυλο-ν-(2-πυριδιλ)αμινο)αιθοξυ)βενζυλο) θειαζολιδινο-2,4-διονη ˙ διepγασια παρασκευης αυτης ˙ πολυμορφες ι,ιι και ιιι αυτης ˙ και χρηση αυτης ως φαρμακευτικο δραστικο συστατικο